Printer Friendly

CYTOTHERAPEUTICS ANNOUNCES BROAD U.S. PATENT COVERING THE USE OF MULTIPLE CELL TYPES IN THERAPEUTIC IMPLANTS

 PROVIDENCE, R.I., March 1 /PRNewswire/ -- CytoTherapeutics, Inc. (NASDAQ: CTII) announced that the U.S Patent and Trademark Office has granted a patent covering the use of two or more cell types enclosed within a membrane as a human therapeutic product. CytoTherapeutics holds the exclusive license patent No. 5,182,111 which was issued to Brown University Research Foundation.
 "The technology covered by this patent expands the applications of our encapsulation technology to treat human disease," according to Seth Rudnick, M.D., chief executive officer of CytoTherapeutics. "It allows us to synergistically combine a therapeutic cell type and a support cell, such as a growth factor secreting cell, within a single, semipermeable capsule that can be implanted into the body.
 "As we look toward the development of our second generation of products," explained Rudnick, "the ability to include a growth factor- secreting cell with a therapeutic cell would enable use cells that have been difficult to grow and sustain within the capsule. Because the growth factor-secreting cell would regulate amount and rate that therapeutic substances are released from the capsule, the scope of serious human diseases that could be treated with encapsulated cell therapy is significantly broadened.
 "Genetically engineered cells are also covered by this patent," he added. "We are not restricted to naturally-occurring cell types."
 Cytotherapeutics believes that, in many instances, production of the desired therapeutic proteins by encapsulated devices will be enhanced by combining growth factor-producing cells with therapeutic-protein- producing cells. The company's technology covered by this patent will potentially have broad application to its CNS (Central Nervous System) programs, For example, the viability and productivity of the company's dopamine-producing implant for the treatment of Parkinson's disease, NeuroCRIB(tm), may be improved by including these two cell types within the same implant.
 CytoTherapeutics' core technology consists of novel techniques for encapsulating living cells or tissue within semipermeable polymer membranes. The membrane protects the cells within the membrane from the body's immune system allows nutrients and oxygen to pass through to the cells and permits the desired therapeutic molecules to pass through to the body, These encapsulated cells can be surgically implanted at the site in the body where they are needed and can be retrieved, if desired or necessary. The company plans to begin human clinical trials on its CereCRIB(tm) implant product for the treatment of severe, chronic pain in Europe within the first half of 1993.
 Inventors on the patent are Dr. Patrick Aebischer, a co-founder of CytoTherapeutics and professor of Biomaterials (Research), Department of Biomedicine, at Brown University; and Dr. Shelley R. Winn, Scientist at CytoTherapeutics.
 CytoTherpaeutics, Inc. of Providence, R.I., was formed in 1989 to develop cellular therapies based on proprietary membrane encapsulation technologies licensed from Brown and Washington Universities. The company's CNS (Central Nervous System) products in development include its CereCRIB(tm) implant, for the treatment of severe, chronic pain, and its NeuroCRIB(tm) implant for the treatment of Parkinson's disease, in addition to its EndoCRIB(tm) implant for the treatment of Type I diabetes.
 -0- 3/1/93
 /CONTACT: Thomas G. Wiggans, chief operating officer, 401-272-3310 ext. 2152, or Elizabeth Razee, communications coordinator, 401-272-3310 ext. 2132, both of CytoTherapeutics/
 (CTII)


CO: CytoTherapeutics, Inc. ST: Rhode Island IN: MTC SU:

DH -- NE008 -- 1273 03/01/93 09:42 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 1, 1993
Words:547
Previous Article:MYCO PHARMACEUTICALS ANNOUNCES SENIOR MANAGEMENT APPOINTMENTS; BARRY BERKOWITZ NAMED PRESIDENT AND CEO, WILLIAM TIMBERLAKE TO HEAD RESEARCH
Next Article:NEW YORK LIFE CHAIRMAN NAMED TO LEAD NATIONAL COMMUNITY AIDS PARTNERSHIP
Topics:


Related Articles
CYTOTHERAPEUTICS REPORTS FIRST QUARTER RESULTS
CYTOTHERAPEUTICS NAMES E. EDWARD BAETGE DIRECTOR OF NEUROSCIENCE
CYTOTHERAPEUTICS ANNOUNCES THIRD QUARTER RESULTS
CYTOTHERAPEUTICS AND GENETIC THERAPY TO INVESTIGATE ENCAPSULATION OF FACTOR IX TO TREAT HEMOPHILIA B
T CELL SCIENCES RECEIVES NOTICE THAT A FUNDAMENTAL U.S. TCAR PATENT WILL ISSUE
CYTOTHERAPEUTICS ANNOUNCES FIRST QUARTER 1993 RESULTS
CYTOTHERAPEUTICS REPORTS THERAPEUTIC DELIVERY OF NERVE GROWTH FACTOR WITHIN BRAIN
CYTOTHERAPEUTICS REPORTS SCIENTIFIC PROGRESS IN PROGRAM TO DELIVER NERVE GROWTH FACTOR (NGF) TO THE BRAIN
CYTOTHERAPEUTICS FILES REGISTRATION STATEMENT FOR OFFERING OF 400,000 UNITS
CYTOTHERAPEUTICS FILES REGISTRATION STATEMENT FOR OFFERING OF 1.5 MILLION SHARES OF COMMON STOCK

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters